Resveratrol Ameliorates Aging-Related Metabolic Phenotypes by Inhibiting cAMP Phosphodiesterases

Sung-Jun Park,1 Faiyaz Ahmad,2 Andrew Philp,4 Keith Baar,4 Tishan Williams,5 Haibin Luo,6 Hengming Ke,5 Holger Rehmann,7 Ronald Taussig,8 Alexandra L. Brown,9 Myung K. Kim,1 Michael A. Beaven,3 Alex B. Burgin,9 Vincent Manganiello,2 and Jay H. Chung1,*

1Laboratory of Obesity and Aging Research, Genetics and Developmental Biology Center
2Cardiovascular Pulmonary Branch
3Laboratory of Molecular Immunology
National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
4Functional Molecular Biology Laboratory, University of California Davis, Davis, CA 95616, USA
5Department of Biochemistry and Biophysics, The University of North Carolina, Chapel Hill, NC 27599-7260, USA
6Structural Biology Lab, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, P. R. China
7Department of Molecular Cancer Research, Centre for Biomedical Genetics and Cancer Genomics Centre, University Medical Center, 3584 CG Utrecht, The Netherlands
8Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
9Emerald BioStructures, 7869 NE Day Road West, Bainbridge Island, WA 98110, USA
*Correspondence: chungj@nhlbi.nih.gov
DOI 10.1016/j.cell.2012.01.017

SUMMARY

Resveratrol, a polyphenol in red wine, has been reported as a calorie restriction mimetic with potential antiaging and antidiabetogenic properties. It is widely consumed as a nutritional supplement, but its mechanism of action remains a mystery. Here, we report that the metabolic effects of resveratrol result from competitive inhibition of cAMP-degrading phosphodiesterases, leading to elevated cAMP levels. The resulting activation of Epac1, a cAMP effector protein, increases intracellular Ca2+ levels and activates the CamKβ-AMPK pathway via phospholipase C and the ryanodine receptor Ca2+-release channel. As a consequence, resveratrol increases NAD+ and the activity of Sirt1. Inhibiting PDE4 with rolipram reproduces all of the metabolic benefits of resveratrol, including prevention of diet-induced obesity and an increase in mitochondrial function, physical stamina, and glucose tolerance in mice. Therefore, administration of PDE4 inhibitors may also protect against and ameliorate the symptoms of metabolic diseases associated with aging.

INTRODUCTION

Calorie restriction (CR) is the most robust intervention demonstrated to extend life span and delay the physiological deterioration associated with aging (McCay et al., 1935). Because CR involves a number of overlapping and interconnected signaling pathways, it is difficult to identify with certainty the mechanism(s) underlying the beneficial effects of CR. Based on studies of the budding yeast Saccharomyces cerevisiae, it was initially proposed that CR extends life span via the activity of Sir2 (Lin et al., 2000), the founding member of the conserved sirtuin family of NAD+-dependent protein deacetylases (Guarente, 2006). Although it remains unclear whether Sir2 plays a direct role in the antiaging effects of CR (e.g., Kaeberlein et al., 2004), overexpression of Sirt1, the mammalian homolog of Sir2, has been reported to protect mice from aging-related phenotypes that are similar to type 2 diabetes (Banks et al., 2008; Bordone et al., 2007; Pfleger et al., 2008), cancer (Herranz et al., 2010), and Alzheimer’s disease (Donmez et al., 2010). Suggesting that Sirt1 activity does not protect against aging-related diseases by delaying the aging process, overexpression of Sirt1 does not extend life span in mice (Herranz et al., 2010).

The positive health effects of CR and sirtuin activity in animal models have provoked intense interest in the development of small-molecule activators of Sirt1 to prevent or delay aging-related diseases. An in vitro screen performed using a fluorophore-tagged substrate identified resveratrol as an activator of Sirt1 deacetylase activity (Howitz et al., 2003). Resveratrol is a natural polyphenol produced by plants in response to environmental stress (Signorelli and Ghidoni, 2005) and is present in many plant-based foods, most notably red wine. Subsequent work has shown that resveratrol extends the life spans of lower eukaryotes (Gruber et al., 2007; Viswanathan et al., 2005; Wood et al., 2004). These studies set the stage for testing resveratrol as a CR mimetic in mammals. In mice, long-term administration of resveratrol induced gene expression patterns that resembled those induced by CR and delayed aging-related deterioration, even though it did not extend life span (Pearson et al., 2008). Resveratrol protected against obesity and development of insulin resistance in rodents fed a high-calorie diet.
AMPK, which is emerging as a key regulator of whole-body metabolism (Beher et al., 2009; Borra et al., 2007; Park et al., 2007; Um et al., 2010). AMPK is a trimeric complex that senses nutrient deprivation by sensing the AMP/ATP (Carling et al., 1987) and ADP/ATP (Xiao et al., 2011) ratios. However, resveratrol can activate AMPK at physiologically relevant concentrations most likely does not involve decreasing energy and increasing the AMP/ATP or ADP/ATP ratios. However, resveratrol can activate AMPK at a concentration less than 10 μM (Dasgupta and Milbrandt, 2007; Park et al., 2007; Um et al., 2010). AMPK is a trimeric complex that senses nutrient deprivation by sensing the AMP/ATP (Carling et al., 1987) and ADP/ATP (Xiao et al., 2011) ratios. AMPK, which is emerging as a key regulator of whole-body metabolism, has been shown to increase NAD+ levels and activate Sirt1 and PGC-1α (Cantó et al., 2009, 2010; Dasgupta and Milbrandt, 2007; Park et al., 2007; Um et al., 2010). However, a causal link between the increase in NAD+ and Sirt1 activation has not been established. We and others have shown that AMPK-deficient mice are resistant to the metabolic effects of resveratrol, providing evidence that AMPK is a key mediator of the metabolic benefits produced by resveratrol (Cantó et al., 2010; Um et al., 2010). These findings demonstrated that activation of Sirt1 and PGC-1α by resveratrol is downstream of AMPK activation.

Studies on how resveratrol activates AMPK have led to different and often conflicting mechanisms. Hawley et al. reported that at a high concentration (100–300 μM), resveratrol decreased ATP; and in a cell line expressing a mutated subunit of AMPK that made AMPK insensitive to AMP, resveratrol did not activate AMPK (Hawley et al., 2010). This suggested that resveratrol, at high concentrations, activated AMPK by decreasing energy and increasing the AMP/ATP or ADP/ATP ratios. However, resveratrol can activate AMPK at a concentration less than 10 μM (Dasgupta and Milbrandt, 2007; Feige et al., 2008; Park et al., 2007). At low concentrations (≤50 μM), resveratrol appears to activate AMPK without decreasing energy (Dasgupta and Milbrandt, 2007; Suchanekova et al., 2009). As the plasma level after oral administration of resveratrol is low (Crowell et al., 2004), the mechanism by which resveratrol activates AMPK at physiologically relevant concentrations most likely does not involve decreasing energy.

For this report, we attempted to find the direct target of resveratrol and to elucidate the biochemical pathway by which it activates AMPK and produces metabolic benefits. We found that resveratrol directly inhibits cAMP-specific phosphodiesterases (PDE) and identified the cAMP effector protein Epac1 as a key mediator of the effects of resveratrol, which leads to the activation of AMPK and Sirt1.

RESULTS

Resveratrol Activates AMPK in an Epac1-Dependent Manner

A hint that cAMP may mediate the effects of resveratrol was suggested by a previous study reporting that resveratrol increased cAMP production in breast cancer cells (El-Mowafy and Alkhaiat, 2003). In this study, we found that cAMP levels increased significantly with a low dose (≤50 μM) of resveratrol in C2C12 myotubes (Figures 1A and 1B). To confirm that resveratrol increased cAMP levels in vivo, we administered resveratrol to mice by oral gavage and measured cAMP levels in skeletal muscle and white adipose tissue (WAT) (Figure S1A available online).

Two findings have raised doubt that resveratrol is a direct Sirt1 activator. First, although resveratrol activates Sirt1 in vivo, it activates Sirt1 to deacetylate fluorophore-tagged substrates but not native substrates in vitro (Beher et al., 2009; Borra et al., 2007; Rodgers et al., 2005), resveratrol increased Sirt1 and PGC-1α activity in mice fed a high-fat diet (HFD) (Lagouge et al., 2006; Um et al., 2010).

An important mediator of the metabolic effects of resveratrol (Lagouge et al., 2006; Um et al., 2010) is peroxisome proliferator-activated receptor γ coactivator, PGC-1α (Puigserver et al., 1998). Consistent with the known ability of Sirt1 to deacetylate and activate PGC-1α (Gerhart-Hines et al., 2007; Rodgers et al., 2005), resveratrol increased Sirt1 and PGC-1α activity in mice fed a high-fat diet (HFD) (Lagouge et al., 2006; Um et al., 2010).

For this report, we attempted to find the direct target of resveratrol and to elucidate the biochemical pathway by which it activates AMPK and produces metabolic benefits. We found that resveratrol directly inhibits cAMP-specific phosphodiesterases (PDE) and identified the cAMP effector protein Epac1 as a key mediator of the effects of resveratrol, which leads to the activation of AMPK and Sirt1.
the Epac-specific agonist 8-(4-chlorophenylthio)-2-O-methyladenosine-3,5-cAMP (also called 007) was sufficient to increase the phosphorylation of AMPK and ACC (Figure 1G). To determine whether resveratrol directly activates Epac, we performed an Epac activity assay in the presence of resveratrol. As shown in Figures S1C and S1D, resveratrol had no direct effect on Epac activity. Together, these findings indicate that resveratrol activates AMPK via Epac1, and resveratrol activates Epac1 indirectly.

Resveratrol Increases NAD⁺ Levels via Epac1
Because AMPK increases NAD⁺ levels and Sirt1 activity (Cantó et al., 2009, 2010; Fulco et al., 2008; Um et al., 2010), the possibility that the resveratrol-mediated increase in NAD⁺ levels is also Epac1 dependent was investigated. We found that the resveratrol-mediated increase in NAD⁺ levels was prevented by Epac1 siRNA but not by control siRNA (Figure 2A). Sirt1-mediated deacetylation of PGC-1α was then examined by immunoprecipitation of PGC-1α and immunoblotting with antibody specific for acetylated Lys. In the presence of Epac1 siRNA, acetylation of PGC-1α was higher and did not decrease after resveratrol treatment (Figure 2B), suggesting that resveratrol activated Sirt1 in an Epac1-dependent manner. To examine whether Epac activity is sufficient to induce mitochondrial biogenesis, myotubes were treated with 007 for 3–4 days before mitochondrial DNA (mtDNA) content was measured. As shown in

**Figure 1. Resveratrol Activates AMPK in an Epac1-Dependent Manner**

(A) Cyclic AMP levels in C2C12 myotubes 30 min after treatment with 0–100 μM resveratrol (Resv).

(B) Cyclic AMP levels in C2C12 myotubes after treatment with resveratrol (50 μM) for the indicated times.

(C) Phosphorylation of AMPK (T172) and AMPK substrate ACC (S79) after treatment with resveratrol (50 μM) in the presence of the AC inhibitor MDL-12,330A in C2C12 myotubes and HeLa cells.

(D) The effect of PKA catalytic subunit α (PKAc) siRNA on resveratrol-induced phosphorylation of ACC and AMPK.

(E) The effect of Epac1 siRNA on resveratrol-induced phosphorylation of ACC and AMPK.

(F) GTP-bound Rap1 was pulled down using the immobilized ras-binding domain (RBD) of RalGDS (left). Quantification of binding is shown on the right (n = 3).

(G) Phosphorylation of ACC and AMPK induced by the Epac agonist 007 (10 μM).

See also Figure S1.
Resveratrol Activates the CamKKβ-AMPK Pathway via the PLC-Ryr2 Pathway

AMPK activation via energy depletion is thought to be dependent on LKB1, and activation of AMPK via increased intracellular Ca²⁺ is dependent on CamKKβ (Hawley et al., 2005; Hurley et al., 2005; Woods et al., 2005). We asked whether resveratrol and Epac1 activate the CamKKβ-AMPK pathway, based on two observations: First, resveratrol has been shown to increase cytosolic Ca²⁺ (Campos-Toimil et al., 2007; Sareen et al., 2007; Vingtdeux et al., 2010). Second, in cardiac myocytes, Epac1 has been shown to increase cytosolic Ca²⁺ in a phospholipase C (PLC)-dependent manner (Oestreich et al., 2007, 2009; Schmidt et al., 2001) via calcium/calmodulin-dependent protein kinase II (CamKII) (Perreira et al., 2007). To examine the potential role of the CamKKβ-AMPK pathway in resveratrol action, we treated myotubes with either the Ca²⁺ chelator BAPTA-AM or the CamKK inhibitor STO609. We found that both BAPTA-AM (Figure 3A) and STO609 (Figure 3B, left) decreased the phosphorylation of AMPK and ACC after treatment with 50 μM resveratrol, indicating that resveratrol stimulated the phosphorylation of AMPK and ACC in a CamKKβ-dependent manner. Because high concentration of resveratrol was reported to activate AMPK by decreasing energy (Hawley et al., 2010), we examined whether the phosphorylation of AMPK and ACC by high concentration of resveratrol (300 μM) was also sensitive to STO609. As shown in Figure 3B (right), STO609 did not affect the phosphorylation of AMPK and ACC after treatment with 300 μM resveratrol, indicating that the phosphorylation of AMPK and ACC by high concentration of resveratrol did not require CamKKβ. To demonstrate that the Epac-induced phosphorylation of AMPK and ACC was also CamKKβ dependent, we treated myotubes with 007 in the presence of STO609 (Figure 3C). We found that STO609 prevented 007 from inducing the phosphorylation of AMPK and ACC. Together, these findings indicate that resveratrol at low concentration activates the CamKKβ-AMPK pathway via Epac1.
As Epac1 increases intracellular Ca\textsuperscript{2+} via PLC, we examined the role of PLC in resveratrol-induced Ca\textsuperscript{2+} release. The resveratrol-induced increase in intracellular Ca\textsuperscript{2+} was significantly reduced in the presence of the PLC inhibitor U73122 (Figure 3D), indicating that resveratrol increased intracellular Ca\textsuperscript{2+} in a PLC-dependent manner. Consistent with this, U73122 prevented resveratrol from stimulating the phosphorylation of AMPK and ACC (Figure 3E). Upon activation of Epac, the ryanodine receptor 2 (Ryr2) is phosphorylated and facilitates the release of Ca\textsuperscript{2+} from the endoplasmic reticulum/sarcoplasmic reticulum (ER/SR) (Wehrens et al., 2004). We treated myotubes with resveratrol in the presence of the Ryr2 inhibitor ryanodine and found that ryanodine prevented resveratrol from stimulating the phosphorylation of AMPK and ACC (Figure 3F). Another ER/SR Ca\textsuperscript{2+}-release channel, the inositol triphosphate (IP3) receptor, which is activated by IP3, does not appear to be involved in resveratrol action because resveratrol was able to stimulate the phosphorylation of AMPK and ACC in the presence of the IP3 receptor inhibitor 2-aminoethoxy-diphenyl borate (2-APB) (Figure S2). We also used Epac1 siRNA to test the Epac1 dependence of CamKK-mediated phosphorylation of Ryr2 residue S2815 (Figure 3G). In agreement with our hypothesis, resveratrol can only induce Ryr2 phosphorylation when Epac1 is active. These findings indicate that resveratrol activates CamKK-β-AMPK via the Epac1-PLC-Ryr pathway.

**Resveratrol Is a Nonselective Phosphodiesterase Inhibitor**

The intracellular levels of cAMP are determined by the activities of ACs, which synthesize cAMP from ATP, and cyclic nucleotide PDEs, which hydrolyze cAMP or cGMP to AMP or GMP, respectively. We measured the effect of resveratrol on the activities of representatives of all three major subclasses of mammalian ACs. As shown in Figure S3A, resveratrol had no effect on AC activity, either in the basal state or in the activated state, suggesting that resveratrol increases cAMP levels by inhibiting PDEs. The PDE superfamily is comprised of 11 types of PDEs (PDE1–11) of which multiple isoforms exist. PDEs have different substrate specificities: PDEs 4, 7, and 8 are cAMP-selective phosphodiesterases, and PDEs 1, 2, 3, 10, and 11 can hydrolyze both cAMP and cGMP, respectively. We measured the effect of resveratrol on the activities of recombinant PDEs 1, 2, 3, 4, and 5 in the presence of cAMP and cGMP to varying degrees. Multiple members of the PDE superfamily are usually expressed in each cell. We measured the activities of recombinant PDEs 1, 2, 3, 4, and 5 in the presence

**Figure 3. PLC and Ryr Are Required for Resveratrol to Activate AMPK**

(A) The phosphorylation of ACC and AMPK induced by resveratrol in C2C12 myotubes in the absence (−) or presence (+) of calcium chelator BAPTA-AM (20 µM). We used myotubes derived from low-passage (<10) C2C12 cells.

(B) The phosphorylation of ACC and AMPK induced by resveratrol in C2C12 myotubes in the absence (−) or presence (+) of the CamKK inhibitor STO609 (5 µg/ml) for 50 µM (left) or 300 µM (right) resveratrol. We used myotubes derived from low-passage (<10) C2C12 cells.

(C) The phosphorylation of ACC and AMPK induced by 007 in C2C12 myotubes in the absence (−) or presence (+) of the CamKK inhibitor STO609 (5 µg/ml). C2C12 cells of <10 passages were used.

(D) The increase in intracellular Ca\textsuperscript{2+} levels after resveratrol treatment (50 µM) in C2C12 myotubes loaded with Ca\textsuperscript{2+} indicator Fluo-4 AM in the presence of PLC inhibitor U73122 (20 µM). F indicates the fluorescence level and ΔF indicates the change in fluorescence (n = 3).

(E) The phosphorylation of ACC and AMPK induced by resveratrol (50 µM) in C2C12 myotubes in the presence (−) or absence (+) of the PLC inhibitor U73122 (20 µM).

(F) Phosphorylation of ACC and AMPK induced by resveratrol in C2C12 myotubes in the absence (−) or presence (+) of the PLC inhibitor U73122 (20 µM).

(G) Resveratrol-induced phosphorylation of S2815 in Ryr2 in the presence of siRNA specific for Epac1 or control siRNA. See also Figure S2.
of resveratrol. We found that resveratrol inhibited PDE1 (IC50 ~6 μM), PDE3 (IC50 ~10 μM), and PDE4 (IC50 ~14 μM) but did not affect the activity of PDEs 2 or 5 (Figure 4A).

To determine how resveratrol inhibits PDEs, we measured the effect of cAMP and resveratrol on the kinetics of recombinant PDE3 activity (Figure 4B). At high concentrations of cAMP, the inhibitory effect of resveratrol on PDE3 disappeared, suggesting that resveratrol is competing with cAMP, and a Lineweaver-Burk plot is consistent with a competitive inhibition mechanism (Figure 4C). To directly demonstrate that resveratrol competes with cAMP in its binding site, we incubated PDE3 with the fluorescent cAMP analog 8-azido-[DY-547]-cAMP, which cross-links to its binding site when stimulated with UV, in the presence of increasing concentrations of either resveratrol or cAMP. Both resveratrol and cAMP competed with 8-azido-[DY-547]-cAMP for the binding site in PDE3 (Figure 4D). Because the binding of 8-azido-[DY-547]-cAMP to PDE3 is irreversible, whereas the binding of resveratrol or cAMP is reversible, the data shown in Figure 4D are an underestimation of the actual competitiveness of cAMP or resveratrol. A simulation of the docking of resveratrol into the catalytic pocket of PDE3 suggests that resveratrol may fit into the catalytic pocket in two orientations (Figures S3B–S3E). Taken together, these findings support the conclusion that resveratrol increases cAMP levels by competitively inhibiting PDEs.

Resveratrol Activates AMPK and Increases Mitochondrial Biogenesis by Inhibiting PDEs

By treating myotubes with specific PDE3 and PDE4 inhibitors, we determined that 76% of the total basal PDE activity was attributable to PDE4 and 18% to PDE3 (Figures 5A and S4). To corroborate our in vitro biochemical findings that resveratrol inhibits PDEs, we sought genetic evidence by using a PDE4 mutation. Previously, it has been shown that the upstream conserved regions (UCRs) of PDE4 increase the sensitivity of PDE4 to competitive inhibitors, whereas the catalytic domain of PDE4, which is missing the UCRs, is more resistant to the known competitive inhibitors (Burgin et al., 2010). We found that the UCRs of PDE4 are also important for inhibition by resveratrol because the resveratrol IC50 of the PDE4 catalytic domain was approximately 2.4-fold higher than that of the full-length PDE4 (~33 μM versus ~14 μM) (Figure 5B). If resveratrol activates AMPK by inhibiting PDE4, resveratrol-induced phosphorylation of ACC and AMPK in myotubes expressing the PDE4 catalytic domain should be reduced compared to those expressing full-length PDE4. As shown in Figure 5C, this was indeed the case.

If the metabolic effects of resveratrol result from inhibiting PDEs, a known PDE inhibitor should produce metabolic effects very similar to those produced by resveratrol. Because PDE4 makes up most of the PDE activity in myotubes, we treated...
Figure 5. Resveratrol Activates AMPK and Increases Mitochondrial Biogenesis by Inhibiting PDEs

(A) The relative contributions of PDE3 and PDE4 to the total PDE (t-PDE) activity in C2C12 myotube lysates were determined by adding either 1 μM cilostamide (PDE3 inhibitor) or 10 μM rolipram (PDE4 inhibitor) to the PDE reaction (n = 3).

(B) The catalytic domain (Cat) of PDE4 is less sensitive to resveratrol than full-length (FL) PDE4. The resveratrol inhibitory curves of recombinant His-tagged PDE4 (FL, Cat) are shown.

(C) The phosphorylation of ACC and AMPK in C2C12 myotubes overexpressing either His-tagged PDE4-FL or PDE4-Cat after they were treated with resveratrol (50 μM) for 3 hr. The levels of PDE4-FL and PDE4-Cat were detected with anti-His antibody.

(D) Cyclic AMP levels in C2C12 myotubes after treatment with rolipram (25 μM) for the indicated times.

(E) The phosphorylation of ACC and AMPK after treatment with rolipram (25 μM) in the presence of control siRNA (Contr) or Epac1 siRNA (Epac1).

(F) The phosphorylation of ACC and AMPK in skeletal muscle (gastrocnemius) after treatment with rolipram (2 mg/kg/day) for 14 weeks.

(G) NAD+, NADH, and the NAD+/NADH ratio in C2C12 myotubes were measured after 1–16 hr of rolipram treatment (25 μM).

(H) Deacetylation of PGC-1α in C2C12 myotubes treated with rolipram (left). Quantification of PGC-1α acetylation/total PGC-1α is shown in the right panel (n = 4).

(I) Expression levels (mRNA) of genes important for mitochondrial biogenesis and function as measured by real-time PCR from skeletal muscle of mice treated with rolipram (n = 4).

(J) mtDNA content in C2C12 myotubes treated with cAMP (100 μM), resveratrol (50 μM), or rolipram (25 μM) for 4 days (n = 5).

(K) mtDNA content in skeletal muscle of mice fed resveratrol (400 mg/kg/day) or rolipram (2 mg/kg/day) for 14 weeks (n = 5).

(L) Mice fed rolipram for 12 weeks were exercised on a treadmill. Running distance prior to exhaustion is shown (n = 5).

Results are expressed as the mean ± SEM. *p < 0.05 and **p < 0.01 between the treatment groups.
myotubes with the PDE4 inhibitor rolipram and found that rolipram increased cAMP to levels similar to those induced by resveratrol in myotubes (Figure 5D). Like resveratrol, rolipram stimulated the phosphorylation of AMPK and ACC in an Epac1-dependent manner (Figure 5E). To demonstrate that rolipram can activate AMPK in vivo, we treated mice with rolipram and harvested skeletal muscle. As shown in Figure 5F, rolipram-treated mice had higher levels of phosphorylated AMPK and ACC than vehicle-treated mice. Like resveratrol, rolipram increased NAD+ levels (Figure 5G) and increased PGC-1α deacetylation (Figure 5H), suggesting that rolipram increased Sirt1 activity.

To test whether rolipram can reproduce the metabolic effects of resveratrol in vivo, we determined the effect of rolipram (2 mg/kg/day) on C57BL6/J mice fed an HFD. After 12–14 weeks of treatment, we isolated skeletal muscle and measured the mRNA levels of genes that are known to be induced by resveratrol and AMPK, such as eNOS, PGC-1α, and others important for mitochondrial biogenesis. We found that rolipram consistently increased the mRNA levels of these genes (Figure 5I). In agreement with this, treatment with resveratrol, rolipram, or cAMP induced mitochondrial biogenesis in myotubes to comparable levels (Figure 5J). Rolipram and resveratrol also increased mitochondrial content to similar levels in mouse skeletal muscle (Figure 5K). To determine whether increased mitochondrial function improved exercise tolerance, we exercised rolipram-treated mice on a treadmill. Rolipram-treated mice ran a significantly greater distance on a treadmill before exhaustion than control mice (445 ± 19 m versus 268 ± 50 m) (Figure 5L). Taken together, these findings indicate that rolipram and resveratrol have very similar effects on mitochondrial biogenesis in skeletal muscle.

**PDE Inhibition Protects against Diet-Induced Obesity and Glucose Intolerance**

The similarity between the effects of rolipram and resveratrol also extended to WAT. As was the case with resveratrol-treated mice (Baur and Sinclair, 2006; Um et al., 2010), the phosphorylation levels of AMPK and ACC were increased in the WAT of rolipram-treated mice (Figure 6A). C57BL6/J mice treated with rolipram were resistant to weight gain on an HFD (Figure 6B) and had less fat content (Figure 6C) even though their food intake was similar to that of control mice (Figure 6D). Decreased weight gain despite normal food intake suggests that rolipram increased the metabolic rate. Because rolipram, like resveratrol and 007, increased the oxygen consumption rate (Figure 2D, right) and fat oxidation in myotubes (Figure 2E), we measured the oxygen consumption rate in rolipram-treated mice. The oxygen consumption rate was increased in rolipram-treated mice (Figure 6E), but physical activity levels were not affected (Figure 6F), indicating that rolipram increased the basal metabolic rate. Consistent with this, both resveratrol- and rolipram-treated mice had higher body temperatures in the fasting state than control mice (Figure 6G). Rolipram, like resveratrol (Um et al., 2010), increased the expression levels of thermogenic genes such as uncoupling proteins (UCPs) and PGC-1α in the adipose tissue (Figure 6H).

PGC-1α increases ROS scavenging capacity (St-Pierre et al., 2003). Consistent with rolipram-treated mice expressing higher levels of PGC-1α, rolipram-treated mice had lower ROS levels (Figure 6I). Considering all of the metabolic changes that rolipram produced, including the reduction of ROS and fat mass and increased mitochondrial function, we expected that rolipram would improve glucose tolerance. Indeed, rolipram-treated mice were more glucose tolerant than were control mice (Figure 6J).

Glucagon-like peptide-1 (GLP-1), which is secreted from the gut, has antidiabetogenic activities, and GLP-1 analogs, as well as drugs that increase the endogenous GLP-1 levels, are part of type 2 diabetes therapy. The expression of GLP-1 is positively regulated by cAMP (Gevrey et al., 2002) and therefore may be induced when either resveratrol and rolipram inhibits PDEs. Supporting this idea, we found that both resveratrol and rolipram increased serum levels of GLP-1 by almost 20% (Figure 6K). Together, these results indicate that both resveratrol and rolipram may protect against type 2 diabetes by diverse mechanisms including hormonal regulation.

**DISCUSSION**

By demonstrating that resveratrol activates the cAMP-Epac1-Sirt1 pathway, this study, in conjunction with previous studies (Beher et al., 2009; Borra et al., 2005; Kaeberlein et al., 2005; Pacholec et al., 2010), explains how resveratrol activates Sirt1 without directly targeting it. Although resveratrol was initially shown to directly activate Sirt1 in an assay that utilized a fluorophore-linked substrate (Howitz et al., 2003), our studies show that resveratrol indirectly activates Sirt1 in vivo due to its effect on cAMP signaling.

Our findings on the mechanism of resveratrol action have implications for other known putative Sirt1 activators such as SRT1720, SRT2183, and SRT1440 (Milne et al., 2007; Pacholec et al., 2010). Like resveratrol, they were discovered as Sirt1 activators by using the fluorophore-tagged substrate and only exhibit Sirt1 activation in the presence of fluorophore-modified substrate. Thus, it is likely that they may also activate Sirt1 via an upstream target in vivo. Because the metabolic effects of SRT1720 are nearly identical to those of resveratrol (Milne et al., 2007; Feige et al., 2008), it is tempting to speculate that these compounds, or at least SRT1720, act via pathways similar to those of resveratrol.

cAMP signaling is highly complex, and its outcomes vary depending on the effector activated by cAMP and on other factors including the cell type, the cellular compartment of cAMP action, and the duration and intensity of cAMP signaling. cAMP is a key mediator of metabolic regulation, and the identification of PDEs as resveratrol targets might explain how resveratrol mimics some aspects of CR. Nutrient deprivation increases cAMP levels as a consequence of increased glucagon and catecholamine signaling and decreased insulin/IGF-1 signaling (Rondinone et al., 2000; Selawry et al., 1973). Resveratrol, by increasing cAMP levels and activating Epac1, may induce some of the pathways that are normally induced during CR (Figure 7). The positive health benefits of PDE4 inhibitors, such as improved memory (Burgin et al., 2010) and protection against aging-related diseases such as Alzheimer’s (Smith et al., 2009) and Parkinson’s (Yang et al., 2008) diseases, have been demonstrated in animal models. It is therefore possible that PDE4 inhibitors...
may be useful for treating metabolic diseases and other aging-related diseases in humans.

**EXPERIMENTAL PROCEDURES**

**Cell Culture**
C2C12 myoblast cells (ATCC) and HeLa cells were maintained in DMEM and 10% fetal bovine serum. To generate C2C12 myotubes, confluent cultures of C2C12 cells were grown in DMEM with 2% horse serum for 3–5 days. We found that C2C12 myotubes generated from early passage (<10 passages after purchase from ATCC) C2C12 myoblast cells yielded most consistent results.

**PDE Assay**
PDE activity was measured by modification of a previously published method (Ahmad et al., 2009; Manganiello and Vaughan, 1973) by using...
Figure 7. Proposed Model of How Resveratrol Mimics CR
Resveratrol inhibits PDE activity and induces cAMP signaling via Epac1, which activates PLCε, resulting in Ca2+ release via the Ryr2 Ca2+ channel and, ultimately, the activation of the CamKKβ-AMPK pathway. CR increases cAMP levels by increasing glucagon and catecholamine levels, which activate AC activity and cAMP production. AMPK increases mitochondrial biogenesis and function by increasing PGC-1α expression, NAD+ levels, and Sirt1 activity. An additional pathway that may contribute to resveratrol action is indicated with dotted lines.

10 nM [3H]cAMP (45000 cpm) or [3H]cGMP as substrates. Less than 10%–15% of the substrates were hydrolyzed during the PDE reaction. Portions of solubilized cell lysates were assayed for PDE activity by incubation with resveratrol (0–100 μM) or with specific PDE inhibitors. Recombinant PDE1 (10 ng) activity was assayed by using 4 μg/ml calmodulin and 0.8 mM Ca2+ together with [3H]cAMP as substrate in the reaction mixture. Recombinant PDE2 (15 ng) activity was assayed in the presence of 1 μM cGMP, which activated it by ~3 fold. Activities of recombinant PDE3 (1 ng) and PDE4 (1 ng) were assayed by incubation in a reaction mixture containing 1 mg/ml BSA, with [3H]cAMP. Recombinant PDE5 (150 ng) activity was assayed using [3H]cGMP as substrate. PDE activity is expressed as pmol of cAMP or cGMP hydrolyzed/min/mg protein. The PDE3 inhibitor cilostamide and the PDE4 inhibitor rolipram were used to define PDE specificity. Recombinant full-length PDE4D was purchased from Signalchem, and the recombinant PDE4D catalytic domain was purchased from Enzo Life Sciences. To measure the activities of PDE3 or PDE4 in C2C12 lysates, PDE activity was measured in the presence of 1 μM cilostamide or 10 μM rolipram.
Animal Experiments
All experiments were approved by the NHLBI ACUC (Animal Care and Use Committee). C57BL/6J mice were originally purchased from Jackson Laboratory. Four- to six-week-old male mice were housed with a 12 hr light-dark cycle (light on 6 am–6 pm) with free access to food and water. For all rolipram-related studies, mice were dosed once daily by oral gavage with 2 mg/kg/day rolipram (Enzo Life Sciences) or with saline and were fed a HFD (40% calories from fat, Research Diets) for up to 14 weeks. To measure the effect of resveratrol on cAMP production, C57BL/6J mice were injected (intraperitoneally [i.p.]) with resveratrol (20 mg/kg body weight) or with DMSO (vehicle). For studies involving chronic resveratrol treatment, C57BL/6J mice were fed a HFD containing resveratrol (400 mg/kg/day) for 14 weeks.

Metabolic Measurements
Body weight and caloric intake were monitored weekly. Plasma glucose was measured by using a glucometer (Ascensia). For the glucose tolerance test, mice were fasted for 16 hr, and 1 mg/g glucose was injected i.p. Blood glucose was measured at 0, 15, 30, 45, 60, and 90 min after injection. Prior to the treadmill endurance tests, the mice were trained for 3 days by running on an Exer-3/6 mouse treadmill (Columbus Instruments) at 10 m/min for 5 min. For the endurance test, the treadmill was set at a 15° incline, and the speed was increased in a stepwise fashion (10 m/min for 10 min followed by 14 m/min for 5 min and then the final speed of 18 m/min). The test was terminated when mice reached exhaustion, which was defined as immobility for more than 30 s. Locomotor activity of mice was measured by photobeam breaks by using the Opto-Varimex-4 (Columbus Instruments). Indirect calorimetry was performed using Oxymax chambers (Columbus Instruments). All mice were acclimatized for 24 hr before measurements. Resting metabolic rate was determined by calculating the average energy expenditure at each 30 min time point during a 24 hr period.

Statistical Analysis
Comparisons between the treatment groups were analyzed by two-tailed Student’s t test, and comparisons involving repeated measurements were analyzed by ANOVA repeated measures. Results are expressed as the mean ± standard error of the mean (SEM). Significance was accepted at p < 0.05.

SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and four figures and can be found with this article online at doi:10.1016/j.cell.2012.01.017.

ACKNOWLEDGMENTS
This work was supported by the Intramural Research Program, National Heart Lung and Blood Institute, National Institutes of Health. We thank Andrew Marks for the Ryr2 phosphoantibody; Dr. Yan Tang for sharing data regarding inhibition of PDE3 by resveratrol; Marije Rensen-De Leeuw and Yan Tang for technical assistance; Shuting Yang and Dalton Saunders for animal management; and Alexandra Brown for manuscript review and comments. H.R. is supported by the Netherlands Organization for Scientific Research (NWO).

Received: May 16, 2011
Revised: November 2, 2011
Accepted: January 5, 2012
Published: February 2, 2012

REFERENCES


mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBIO J. 26, 1913–1923.


EXTENDED EXPERIMENTAL PROCEDURES

siRNA
The human Epac1 siRNA and PKAc (α) siRNA were purchased from Dharmacon. Control siRNA was also from Dharmacon. Epac1 and PKAc (α) were knocked down by transfecting HeLa cells with siRNA by using Lipofectamine 2000 according to the manufacturer’s protocol. Four days after transfection, cells were harvested and lysed.

Cyclic AMP Measurement
The cyclic AMP complete enzyme immunoassay kit from Assay Designs was used as directed by the manufacturer.

ROS Measurements
ROS levels were determined in muscle extracts using the ROS-sensitive fluorescent dye dichlorodihydrofluorescein (DCF). Briefly, oxidation-insensitive dye (carboxy-DCFDA) was used as a control to ensure that changes in the fluorescence seen with the oxidation sensitive dye (H2DCFDA) were due to changes in ROS production. Oxidation insensitive and oxidation-sensitive dyes were first dissolved at a concentration of 12.5 mM and diluted with homogenization buffer to 125 μM immediately before use. Diluted dyes were added to tissue extract (100 μg) in a 96-well plate to achieve a final concentration of 25 μM. The change in fluorescence intensity was monitored at two time points (0 and 30 min) by using a microplate fluorescence reader (Bio-Tek Instruments), with excitation set at 485 nm and emission set at 530 nm.

Photoaffinity Labeling
Photoaffinity labeling of PDE3 with the fluorescent cAMP analog 8-azido-[DY-547]-cAMP was carried out in 0.1 ml total volume containing 50 mM HEPES (pH 7.5), 250 mM NaCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.1 mM DTT, 5 μg ovalbumin, 0.2 mM 8-azido-[DY-547]-cAMP (Axxora), 1.5 mM IBMX, protease inhibitor cocktail (Roche), and with the indicated concentrations of cAMP or resveratrol. After incubation (96-well cell culture plates, 30 min on ice, in darkness), samples were irradiated (15 min) with a mineral lamp (Ultraviolet products, 254 nM) positioned 6 cm above the top of the plates. Reactions were terminated by boiling in Laemmli SDS sample buffer and subjected to SDS-PAGE. Binding of fluorescent 8-azido-cAMP was detected by scanning with Typhoon (Amersham).

Body Temperature Measurement
Temperature was determined between 9 am and 11 am (room temperature was 22 °C ± 1 °C) with a rectal probe (Physitemp Instruments) connected to a portable thermometer (TH-5 Physitemp instruments).

Fat Index Calculation
Fat mass was first measured by NMR spectroscopy by using a Minispec (Bruker Biospin Corporation, Houston, TX). Fat index was calculated by dividing the fat mass by total body weight.

Docking Analysis
The crystal structure of PDE3B catalytic domain (PDE entry code of 1SOJ) and AutoDock 4.2 (Huey et al., 2007) was used for docking of resveratrol. A grid box with 90 × 90 × 90 points equally spaced at 0.375 Å was generated using AutoGrid. Parameters used for Lamarckian genetic algorithm (LGA) were as follows: random initial orientation and position, population size (150), maximum number of energy evaluations (25 million), maximum number of generations (27,000), mutation rate (0.02), crossover rate (0.8), and 100 docking runs. The final 100 conformations produced by this docking method were clustered if their root-mean-square deviations differed by less than 2.0 Å.

mtDNA Quantification
Relative amounts of nuclear DNA and mtDNA were determined by quantitative real-time PCR. The ratio of mtDNA to nuclear DNA reflects the mitochondrial content in a cell. Muscle tissue (gastrocnemius) was homogenized and digested with Proteinase K overnight in a lysis buffer for DNA extraction by using the DNeasy kit (QIAGEN). Quantitative PCR was performed by using the following primers: mtDNA-specific PCR, forward 5’- CCGCAAGGGAAAGATGAAAGA-3’, reverse 5’-TCGTGGTGTTTCGGGTTTTC- 3’; and nuclear DNA-specific PCR, forward 5’-GCCAGGCCTCTCCTGATGT-3’, reverse 5’-GGGAACAAAAGACCTCTTCTGG-3’ and SYBR Green PCR kit in a prism 7500HT sequence detector (Applied Biosystem) with a program of 20 min at 95 °C, followed by 50 to 60 cycles of 15 s at 95 °C, 20 s at 58 °C, and 20 s at 72 °C. mtDNA content was normalized with nuclear DNA content.

Transfection of Full-Length and Catalytic Domain PDE4
Expression vectors for full-length PDE4 and the catalytic domain of PDE4 were constructed by inserting the cDNA encoding His-tagged full-length PDE4D7 or the catalytic domain of PDE4D (Burgin et al., 2010) into the mammalian expression vector pCDNA3. Subconfluent C2C12 myocytes (80%) were transfected by using the Lipofectamine 2000 transfection reagent with expression vectors for full-length PDE4 or the catalytic domain of PDE4. Myocytes were then differentiated into myotubes according to the standard protocol by using DMEM containing 2% horse serum.
Oxygen Consumption Rate Measurements in C2C12 Myotubes

C2C12 cells were seeded in XF 24-well cell culture microplates (Seahorse Bioscience, North Billerica, MA) at 2.0–3.0 \times 10^4 cells/well (0.32 cm²) in 250 \mu l high glucose DMEM growth medium supplemented with 10% fetal bovine serum and 1% pen/strep. Following 24 hr, cells were switched to low serum media (2% horse serum, 1% pen/strep) to induce differentiation. Cells were fed every 24 hr for 4 days. On the day of testing, 10 \mu M of resveratrol, 25 \mu M of rolipram or DMSO as a vehicle control were suspended in fresh DMEM media and the cells were returned to the incubator for 6 hr. After 6 hr, cells were washed twice with 500 \mu l assay medium (unbuffered low glucose DMEM supplemented with pyruvate and glutamine, pH 7.4). A final volume of 600 \mu l of assay medium was added to each well prior to the experimental protocol. Cells were then transferred to a CO₂ free incubator, maintained at 37°C for 1 hr before the start of the assay. Following assay calibration, measurements of oxygen consumption rate (OCR) were performed every 10 min for 2.5 hr. At 30, 60, 90, and 120 min, 75 \mu l of palmitoleate (100 \mu M)/2% BSA was injected sequentially into each well and the effect on OCR was determined. At the end of the assay, media was aspirated, cells were washed twice with cold PBS, and cells were collected from each plate in 50 \mu l lysis buffer containing protease inhibitors (50 mM Tris pH 7.5; 250 mM Sucrose; 1 mM EDTA; 1 mM EGTA; 1% Triton X-100; 1 mM NaVO₄; 50 mM NaF; 0.10% DTT; 0.50% protease inhibitor cocktail) and protein content was determined by using the DC protein assay (Biorad, Hercules, CA). The oxygen consumption rate was normalized to protein content.

Reagents

[^3H]cAMP was from Amersham. Purified recombinant PDE1, PDE2, PDE4, and PDE5 were obtained from Signalchem. Flag-PDE3B was purified from SF21 cell lysates using a Flag-agarose (Sigma) affinity column. Recombinant PKA-R2 and recombinant PKA holoenzyme were obtained from Sigma and Biaffin (Germany), respectively. Rolipram, ryanodine, and U73122 were purchased from Calbiochem.

Immunoblotting

Cells were lysed in RIPA buffer and subjected to immunoblotting. For tissue extraction, samples were pulverized in liquid nitrogen and homogenized in a lysis buffer. The following antibodies were used: AMPK, p-AMPK (T172), phospho-ACC, which recognizes phosphorylated Ser79 in ACC1 or phosphorylated Ser22 in ACC2 and ACC (Cell Signaling Technology); Sirt1 (Upstate Biotechnology), V5 (Invitrogen), and Actin (Santa Cruz). PGC-1α acetylation was visualized by immunoprecipitation from the cell extract (500 \mu g) using PGC-1α antibody (Santa Cruz) followed by immunoblotting with antibody specific for acetylated lysine (Cell Signaling Technology) or for PGC-1α. Levels of PGC-1α acetylation were then quantified by scanning densitometry.

Ca²⁺ Signal Measurements

C2C12 myoblasts were seeded on a 96-well plate (Perkin Elmer). After differentiation, they were preincubated with 20 \mu M U73122 for 1 hr. Ca²⁺ release was measured using the fluorescent calcium indicator Fluo-4AM (Molecular Probes) according to manufacturer’s suggestions. Ca²⁺ increases are reported as ΔF/F ([F – Fbasal]/Fbasal), where F indicates fluorescence.

Real-time PCR

Total RNA was isolated by using the TRIzol reagent extraction kit (Invitrogen), according to the manufacturer’s instructions. RNA was subsequently reverse transcribed to cDNA by using the high capacity cDNA archive kit (ABI). The mRNA levels were measured by real time PCR using the ABI PRISM™ 7900HT Sequence Detection System (Applied Biosystems).

NAD⁺/NADH Ratio Measurements

The NAD⁺/NADH ratio was measured from whole-cell extracts of C2C12 myotubes using the NAD⁺/NADH quantification kit from Biovision based on an enzymatic cycling reaction, according to the manufacturer’s instructions.

AC Activity Measurements

AC activity was expressed in SF9 cells and SF9 membranes containing individual AC isoforms were prepared as described elsewhere (Tausig et al., 1994). AC activity was measured using the procedure previously described (Smigel, 1986). All assays were performed for 10 min at 30°C in a final volume of 100 \mu l containing 10 \mu M of AC expressing SF9 membrane protein and a final concentration of 10 mM MgCl₂. Forskolin and resveratrol were added to the assay tube to a final concentration of 100 \mu M when tested. Assays were performed in duplicate and the results are represented as mean ± standard deviation (SD) of two experiments.

EPAC Assay

Measurements were performed essentially as previously described (Rehmann, 2006), but with the use of the fluorescence GDP analog GDP-BODIPY (Molecular Probes) instead of mant-GDP. Briefly, 200 nM Rap1B preloaded with GDP-BODIPY was incubated in the presence of 100 nM Epac1 (residues 149–881) and an excess of 20 \mu M GDP and in the presence chemicals as indicated. Nucleotide exchange is monitored as a decrease in the fluorescence signal over time, since Rap bound GDP-BODIPY displays approximately five times higher fluorescence intensity than does free GDP-BODIPY in the buffer solution.
Serum GLP-1 Measurement
Serum GLP-1 levels were measured using GLP-1 (active) ELISA (Millipore), according to the manufacturer’s directions.

Rap1 Pull-Down Assay
pGEX Ral GDS-RA, an expression vector for GST-RalGDS-RBD, was transformed into Escherichia coli (strain BL21). Protein production was initiated by addition of isopropyl β-D-thiogalactopyranoside (IPTG) to the culture. The fusion protein was affinity purified on a glutathione Sepharose 4B column (Amersham Bioscience) from the supernatant of bacteria lysed by sonication. GST-RalGDS-RBD precoupled to a glutathione Sepharose 4B column was added to the cell lysates and incubated at 4°C for 60–180 min with slight agitation. Beads were washed four times in lysis buffer and subjected to immunoblotting.

SUPPLEMENTAL REFERENCES
Figure S1. The Effect of Resveratrol on cAMP Levels, Related to Figure 1

(A) Cyclic AMP levels in mouse skeletal muscle and white adipose tissue (WAT) after administration of resveratrol by oral gavage (100 mg/kg) (n = 4). *p < 0.05 compared to vehicle-treated (0 min).

(B) Cyclic GMP levels in C2C12 myotubes 30 min after treatment with the indicated concentrations of resveratrol.

(C and D) Resveratrol does not affect EPAC activity. The effect of resveratrol (100 μM) or vehicle on EPAC activity in the absence or presence of 100 μM (C) or 10 μM (D) cAMP.
Figure S2. The IP3 Receptor Is Not Essential for Resveratrol to Activate AMPK, Related to Figure 3

C2C12 myotubes were treated with resveratrol either in the presence (+) or absence (−) of the IP3 receptor antagonist 2-APB.

<table>
<thead>
<tr>
<th>2-APB:</th>
<th>−</th>
<th>+</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resv (hr):</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>p-AMPK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMPK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Actin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Figure S3. Resveratrol Is a PDE Inhibitor, Related to Figure 4**

(A) Resveratrol does not affect AC activity. AC activity of AC2, AC6, and AC8 was measured in the presence of resveratrol (100 μM) or DMSO both before (basal) and after stimulation with forskolin (FSK) (n = 2). Results are expressed as the mean ± SD.

(B) Simulated binding of resveratrol to PDE3B. The binding energy and dissociation constant (K_d) are shown for each cluster.

(C) Simulated binding of the representative of docked cluster #1 resveratrol (pink sticks) to the PDE3B active site. Interacting residues are shown in yellow sticks. Colors red and blue represent oxygen and nitrogen, respectively. The hydrogen bonds are indicated with dotted lines.

(D) Simulated binding of the representative of docked cluster #3 resveratrol (green sticks) to the PDE3B active site.

(E) A surface model of the overlays of the two main docked conformations of resveratrol (sticks) into the pocket of PDE3B.

Explanation of the docking results: To investigate how resveratrol may bind to the active site of PDE3, the crystal structure of the PDE3B catalytic domain (Scapin et al., 2004) was used as the template for docking of resveratrol. The hundred docked conformations output from program AutoDock 4.2 (Huey et al., 2007) can be clustered into two major groups that account for 32% and 64% of the total population (panel B). Cluster #1 has the lowest binding energy and the simulated dissociation constant (K_d) of 3–9 μM. The oxygen atom of the tyrosyl group forms a hydrogen bond with Asp937 on one end of resveratrol while the oxygens of the 2,4-dihydroxybenzenyl group on the other end forms three hydrogen bonds with His948, Thr952, and Gln988 (panels C and E). In addition, the models in cluster #1 contact via van der Waals force with residues of Tyr736, Leu951, Ile955, Gln988, and Phe991. Cluster #3 has a larger K_d at 7–11 μM and forms only two hydrogen bonds with His948 on one end of resveratrol and with His736 on another end, respectively (panel D and E). The models in cluster #3 form van der Waals interactions with the similar set of residues as cluster #1 does, although the interactions of individual atoms in two clusters are different. An invariant glutamine, Gln988 in PDE3B, has been shown to form hydrogen bonds with substrates and inhibitors in all PDE families (Ke and Wang, 2007). However, the resveratrol model shows that cluster #1, but not cluster #3, forms a hydrogen bond with Gln988.
Figure S4. Inhibitors of PDE3 and PDE4 Are Highly Specific, Related to Figure 5

Phosphodiesterase activities of recombinant PDE3 and PDE4 were measured in the presence of PDE3 inhibitor cilostamide (Cil) and PDE4 inhibitor rolipram (Rol).